Two Sigma Securities, LLC Bio N Tech Se Call Options Transaction History

Two Sigma Securities, LLC

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	SELL	$88.96 - $112.35 $400,320 - $505,575	-4,500 Reduced 30.41%	10,300 $950,000
Q4 2023 Feb 14, 2024	BUY	$90.91 - $112.75 $854,554 - $1.06 Million	9,400 Added 174.07%	14,800 $1.56 Million
Q3 2023 Nov 14, 2023	SELL	$98.5 - $125.08 $265,950 - $337,716	-2,700 Reduced 33.33%	5,400 $586,000
Q2 2023 Aug 14, 2023	SELL	$102.58 - $129.66 $1.24 Million - $1.57 Million	-12,100 Reduced 59.9%	8,100 $874,000
Q1 2023 May 15, 2023	BUY	$122.57 - $153.67 $2.48 Million - $3.1 Million	20,200 New	20,200 $2.52 Million

Q2 2022 Aug 15, 2022	SELL	$123.25 - $186.24 $1.77 Million - $2.68 Million	-14,400 Reduced 58.06%	10,400 $1.55 Million
Q1 2022 May 16, 2022	BUY	$126.25 - $231.85 $2.94 Million - $5.4 Million	23,300 Added 1553.33%	24,800 $4.23 Million
Q4 2021 Feb 14, 2022	SELL	$216.64 - $362.52 $2.34 Million - $3.92 Million	-10,800 Reduced 87.8%	1,500 $387,000
Q3 2021 Nov 15, 2021	BUY	$205.93 - $447.23 $1.94 Million - $4.2 Million	9,400 Added 324.14%	12,300 $3.36 Million
Q2 2021 Aug 16, 2021	BUY	$113.32 - $241.49 $328,628 - $700,321	2,900 New	2,900 $649,000

327

40.4M

1.31M

1.37M

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $19.5B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

Get notified when there are updates to the investment portfolio of Two Sigma Securities, LLC, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Securities, LLC with notifications on news.